We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Bruker Daltonics and Protein Discovery Announce Co-Marketing Agreement

Bruker Daltonics and Protein Discovery Announce Co-Marketing Agreement

Bruker Daltonics and Protein Discovery Announce Co-Marketing Agreement

Bruker Daltonics and Protein Discovery Announce Co-Marketing Agreement

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bruker Daltonics and Protein Discovery Announce Co-Marketing Agreement "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bruker Daltonics Inc. and Protein Discovery, Inc. have announced that they intend to collaborate on introducing scientists to the protein biomarker discovery capabilities of MALDI molecular imaging mass spectrometry.

Protein Discovery holds a license from Vanderbilt University to provide imaging mass spectrometry services, and provides these services to customers in the research, pharmaceutical and diagnostics industries.

Bruker Daltonics manufactures and sells the MALDI Molecular Imager™ (for research use only) that has been optimized for this technique in collaboration with Professor Richard Caprioli at Vanderbilt University.

Both companies anticipate significant synergy effects from the collaboration, as both expect to benefit from the increasing popularity of MALDI imaging mass spectrometry.

MALDI molecular imaging mass spectrometry reads cell type specific protein and peptide mass spectra directly from sliced tissues.

The imaging resolution of the technique enables differential mass spectrometry analysis of adjacent tissue types within a single tissue slice, such as cancerous vs. non-cancerous regions.

Protein Discovery's MALDI imaging mass spectrometry service laboratory is outfitted with Bruker Daltonics' instrumentation.

"The capabilities and applications of MALDI imaging mass spectrometry have now been well documented in the scientific literature by researchers who picked up on it early," said Chuck Witkowski, chief executive officer at Protein Discovery.

"However, until recently, there was little vendor support for imaging mass spectrometry, so biologists and research clinicians couldn't really see what the technique could accomplish for their own research."

"With the Bruker Daltonics MALDI Molecular Imager we now can show them the power of this new technique on their own research samples."

"We're already conducting a number of pilot-scale projects for research groups looking for cell type specific protein spectra that they can map directly onto a histological tissue slice image."

Dr. Michael Schubert, Executive Vice President of Bruker Daltonics, stated, "Our recently introduced MALDI Molecular Imager is the leading mass spectrometry platform for imaging the spatial distribution of peptide and protein biomarkers in tissue sections."

"Enabled by our unique and proprietary smartbeam™ technology, the MALDI Molecular Imager generates results very quickly and with unrivalled data quality. Visualization of the spatial distribution of peptides and proteins is a powerful new tool in the fields of biomarker validation and drug development."

"Protein Discovery has significant expertise in applying MALDI molecular imaging mass spectrometry and we are very pleased to enter into this partnership with them."